Radical therapy may halt progress of MS
Scientists in Canada described as “very exciting” the results from a trial of 24 patients who have a highly active, relapsing form of the autoimmune disease.
However, they warned that the procedure was risky, and only likely to benefit a proportion of patients in early stages of the illness.



